ABIO NASDAQ
ARCA biopharma, Inc.
1W: +10.8%
1M: +55.8%
3M: +24.6%
1Y: +123.8%
3Y: +51.1%
5Y: -11.7%
$28.80
Last traded 2024-08-30 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$0
+0.0% ▲
Gross Profit
$0
+0.0% ▲
Operating Income
-$122M
+0.0% ▲
Net Income
-$105M
+0.0% ▲
EPS (Diluted)
$-154.03
+0.0% ▲
EBITDA
-$122M
+0.0% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% |
| Cost of Revenue | $93K | $91K | $114K | $111K | $0 |
| Gross Profit | -$93K | -$91K | -$114K | -$111K | $0 |
| Gross Margin | — | — | — | — | — |
| R&D Expenses | $5M | $14M | $5M | $1M | $101M |
| SG&A Expenses | $5M | $6M | $6M | $6M | $21M |
| Operating Expenses | $10M | $19M | $11M | $7M | $122M |
| Operating Income | -$10M | -$19M | -$10M | -$7M | -$122M |
| Operating Margin | — | — | — | — | — |
| Interest Expense | $9K | $0 | $675K | $0 | $0 |
| Income Before Tax | -$10M | -$19M | -$10M | -$5M | -$105M |
| Tax Expense | -$9K | -$91K | -$670K | $0 | $0 |
| Net Income | -$10M | -$19M | -$10M | -$5M | -$105M |
| Net Margin | — | — | — | — | — |
| EPS (Diluted) | $-2.07 | $-1.39 | $-0.69 | $-0.37 | $-154.03 |
| EBITDA | -$10M | -$19M | -$10M | -$7M | -$122M |
| Shares Outstanding | 5M | 14M | 14M | 14M | 45614 |